Most recently, Cohen worked as the chief scientific officer in Rosetta Genomics, a developer of microRNA-based molecular diagnostics.
Asterand CEO Martyn Coombs said that Cohen has a reputation as an innovative scientist with an in-depth knowledge of drug discovery and development, oncology, personalised medicine and diagnostics.
Asterand CSO Dalia Cohen said that through the acquisition of BioSeek, Asterand has added the possibility of using sophisticated human primary cell based models and screening to predict at an early stage whether compounds will work in patients. She is eager to direct Asterand’s scientific strategy to maximise its growth potential over the long term.”